Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.

Osnat Bairey, Rosa Ruchlemer, MD, Naomi Rahimi-Levene, Yair Herishanu, MD, Andrei Braester, MD, Abraham Klepfish, MD, Lev Shvidel

Blood (2010) 116 (21): 4620.

https://doi.org/10.1182/blood.V116.21.4620.4620

Published: 2010

Journal Articles

Addition of Fresh Frozen Plasma to Rituximab Induces a Major Clinical and Laboratory Response in Patients with Refractory Advanced CLL.

Abraham Klepfish, MD, Amichay Schattner, MD, Iannis Kotsianidis, MD, Daniela Goldshtein, MD, Hussam Ghoti, MD, Paulina Patchenko, MD, Eliezer Rachmilewitz, MD

Blood (2007) 110 (11): 4723.

https://doi.org/10.1182/blood.V110.11.4723.4723

Published: 2007

Journal Articles

Addition of Fresh Frozen Plasma to Rituximab Induces a Major Clinical and Laboratory Response in Patients with Refractory Advanced CLL.

Abraham Klepfish, MD, Amichay Schattner, MD, Ioannis Kotsianidis, MD, E.A. Rachmilewitz, MD

Blood (2006) 108 (11): 4986.

https://doi.org/10.1182/blood.V108.11.4986.4986

Published: 2006

Journal Articles

Retrospective Analysis of Clinical Parameters and Survival Data in Patients with Chronic Lymphocytic Leukemia of Younger Versus Older Age Groups.

Abraham Klepfish, MD, M. Sarid, PhD, M. Basalov, MD, H. Ghoti, MD, E.A. Rachmilewitz, MD

Blood (2005) 106 (11): 5001.

https://doi.org/10.1182/blood.V106.11.5001.5001

Published: 2005

Journal Articles

Successful Induction of a Rapid Improvement of Both Clinical and Laboratory Parameters in a Patient with Advanced CLL by Combining Rituximab with Fresh Frozen Plasma as a Source for Complement. A Novel Therapeutic Approach?.

Abraham Klepfish, MD, H. Ghoti, MD, E.A. Rachmilewitz, MD

Blood (2005) 106 (11): 5030.

https://doi.org/10.1182/blood.V106.11.5030.5030

Published: 2005

Journal Articles

An IELSG International Survey of Primary Effusion Lymphoma (PEL).

Blood (2004) 104 (11): 3265.

https://doi.org/10.1182/blood.V104.11.3265.3265

Published: 2004

NARROW

Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.

Addition of Fresh Frozen Plasma to Rituximab Induces a Major Clinical and Laboratory Response in Patients with Refractory Advanced CLL.

Addition of Fresh Frozen Plasma to Rituximab Induces a Major Clinical and Laboratory Response in Patients with Refractory Advanced CLL.

Retrospective Analysis of Clinical Parameters and Survival Data in Patients with Chronic Lymphocytic Leukemia of Younger Versus Older Age Groups.

Successful Induction of a Rapid Improvement of Both Clinical and Laboratory Parameters in a Patient with Advanced CLL by Combining Rituximab with Fresh Frozen Plasma as a Source for Complement. A Novel Therapeutic Approach?.

An IELSG International Survey of Primary Effusion Lymphoma (PEL).

Email alerts

ASH Publications

American Society of Hematology

Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.

Addition of Fresh Frozen Plasma to Rituximab Induces a Major Clinical and Laboratory Response in Patients with Refractory Advanced CLL.

Addition of Fresh Frozen Plasma to Rituximab Induces a Major Clinical and Laboratory Response in Patients with Refractory Advanced CLL.

Retrospective Analysis of Clinical Parameters and Survival Data in Patients with Chronic Lymphocytic Leukemia of Younger Versus Older Age Groups.

Successful Induction of a Rapid Improvement of Both Clinical and Laboratory Parameters in a Patient with Advanced CLL by Combining Rituximab with Fresh Frozen Plasma as a Source for Complement. A Novel Therapeutic Approach?.

An IELSG International Survey of Primary Effusion Lymphoma (PEL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only